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Background: The objective of the current study was to determine the incidence, clinical and 
pathologic characteristics, and outcome of patients with conventional osteosarcoma who developed 
metachronous tumours and treated by limb salvage surgery with Custom Mega Prosthesis.
Methods: Among 1198 osteosarcoma patients who were treated with limb salvage surgery and 
implantation of custom mega prosthesis, 6 patients were found to have metachronous lesions. The 
absence of pulmonary metastases was conﬁrmed by chest radiographs and computed tomography 
while radionuclide bone scan and biopsy were used to conﬁrm the absence of skeletal metastases. The 
patients were treated by limb salvage surgery with custom mega prosthesis for the metachronous 
tumour and functional outcome was evaluated by MSTS scores. 
Results: Index primary tumours involved the femur (n=3) and the tibia (n=3) and were treated with 
limb salvage surgery using endoprosthetic reconstruction. Single metachronous tumours developed in 
the all of these patients with the interval between identiﬁcation of the primary tumour to development 
of the metachronous tumours varying from 18 months to 41 months. All metachronous tumours were 
treated with neoadjuvant chemotherapy and limb salvage surgery. We obtained excellent functional 
outcome for primary tumours and good functional outcome for metachronous tumours. Two patients 
succumbed to disease due to pulmonary and cerebral metastasis during follow-up. 
Conclusions: With advances in survival rate in the multidrug chemotherapy era in the post tumours-
resection period, advanced diagnostic modalities help in diagnosing metachronous osteosarcoma. It 
should be recognized as important sequelae in long-term survivors. Meticulous follow-up is required to 
permit early detection and successful therapeutic intervention. Limb salvage surgery has provided 
consistent good results in metachronous osteosarcoma patients.  
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ABSTRACT
Introduction
 E igh ty  pe rcen t  o f  pa t i en t s  w i th 
osteosarcoma are known consistently to harbour 
micro-metastases in the lungs at the time of 
diagnosis (1). These metastases are undetected 
in imaging studies. Untreated, they are detected 
6–9 months later and usually are responsible for 
the patient's mortality. In a rather smaller group, 
skeletal metastases with soft tissue invasion 
were present with pulmonary metastasis.
 In contrast, skeletal lesions may appear 
later, after treatment of the primary tumours in 
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the absence of pulmonary metastasis. These 
lesions are designated as metachronous tumours. 
They did not metastasize from the primary 
tumours or the lungs but developed later and 
spontaneously in other parts of the skeleton.
Materials and Methods
 During the past 28 years, 1198 patients of 
osteosarcoma were treated by the senior author 
(MVN). All these patients had osteosarcoma at 
one site at the time of initial diagnosis. They 
were treated with neoadjuvant multidrug 
chemothe rapy,  t umour  r e sec t ion  and 
implantation of custom mega prosthesis. 
Henceforth they were serially monitored for the 
presence of detectable pulmonary and skeletal 
metastases. Six of 1198 patients were identiﬁed 
with single post-therapy metachronous 
osteosarcomas. Before the discovery of the 
metachronous tumours, the lungs and skeleton 
had been continually free of disease.
Results
 The primary lesions in these 6 patients 
were located in the following sites: distal femur 
(n=3), proximal tibia (n=2) and distal tibia 
(n=1). These metachronous tumours appeared as 
single lesions in all these 6 patients. They were 
located in the proximal humerus (n=2), proximal 
tibia (n=1), tibial diaphysis (n=1), proximal 
femur (n=1) and distal radius (n=1).  The 
metachronous tumours occurred at long bones in 
83% (5 out of 6 sites). Among the 6 patients who 
developed metachronous osteosarcoma, the 
mean age was 24.2 years and 5 out of 6 patients 
were males. The interval between the diagnoses 
of the primary tumours and the metachronous 
tumours varied from 18 to 41 months. Selected 
illustrations of primary and metachronous 
tumours in individual patients are depicted in 
Fig. 1 and 2.
 The metachronous tumours, presented 
with characteristics similar to those of the 
primary tumours. Histologic characteristics of 
the primary tumours were as follows: 
osteoblastic (n=3), chondroblastic (n=2) and 
periosteal (n=1). The diagnosis of all 6 
metachronous tumours were conﬁrmed by 
biopsy. The histology in 6 metachronous 
t u m o u r s  w e r e  c o n c o r d a n t  w i t h  t h e 
corresponding primary tumours detected prior. 
The average survival period of these patients 
post-treatment of the metachronous tumours 
was 2.45 years, with 2 succumbing to disease at 
8th and 18th month of follow-up. The mean 
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Fig. 1: Metachronous osteosarcoma ( PT - PH ) 
SITE 2 ( after 2 yrs FU)
Intra-op Post-op Pre-op Intra-op Post-op
5 yrs FU
SITE 1
 Pre-op
Musculoskeletal Tumour Society Score (MSTS) 
score for functional outcome of primary tumours 
was 22.9 while for metachronous tumours was 
19.5 with poorer outcome noted at proximal 
humerus and distal tibia. The patients' details are 
depicted in Table 1.
Discussion
 Lungs are the most common site for the 
development of metastases in patients with 
osteosarcoma. Skeletal metastases although less 
common, about 3.6-10%, also were reported in 
early studies and are generally in association 
with pulmonary metastases (1). Lockshin and 
Higgins (2) similarly reported a 41% incidence 
of bone metastases among 22 osteosarcoma 
patients who were dying in hospital. These 
metastases were detected radiologically or at 
autopsy. 
 Compared  wi th  the  de tec t ion  o f 
p u l m o n a r y  a n d  s k e l e t a l  m e t a s t a s e s 
(concurrently or later), the detection of single or 
multiple skeletal lesions without pulmonary 
involvement  subsequent  to  the ini t ia l 
presentation of the primary tumour has been 
relatively uncommon. These lesions were 
termed as metachronous lesions (3). Several 
early reports suggested a multicentric origin and 
reported most lesions discovered in the absence 
of pulmonary metastases (4-13). This ﬁnding is 
in concurrence with our deﬁnition.  These 
metachronous skeletal sites generally were 
similar to the sites affected by primary 
osteosarcoma. Corradi et al (14) reported 26 
patients with 59 metachronous lesions with 76% 
of  s i tes  a t  long bones and 62% male 
pred ispos i t ion .  We repor t  6  cases  o f 
metachronous tumours in 1198 osteosarcoma 
patients (incidence: 0.5%) with 83% sites at long 
bones and 83% male predisposition.
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Fig. 2: Metachronous osteosarcoma ( PT - PH ) 
SITE 1 SITE 2 ( after 4 yrs FU)
Intra-op Post-op Pre-op Post-op
4.5 yrs FU
Pre-op
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Table1: Demographic details of limb salvage surgery for metachronous osteosarcoma (OS)
Sl. 
No.
Name/P
atient 
(Pt. 
No.)
Age /
Sex
Site 1 Diagnosis (A) Site 1 
Treatment
Site 2 Diagnosis 
(B)
Interval 
duration
(Yrs)
Site 2 
Treatment
MSTS 
Score
Outcome
1. Pt1: ML 30/
M
Right Distal Femur 
(DF)
 
OS with 
Metases
 
-2004
 
CMP Right
 DF
 
Right Distal
 Radius (DR)
 OS-
 
2007
 
3
 
CMP Right
 DR
 
A:
 
24
 B:
 
21
 
1.5yrs; Recurrence of 
Metases/ Spine/Pelvis; died 
of disease
 
2. Pt2: SH 18/F Left Proximal Tibia 
(PT) OS-
 
2005
 
CMP Right
 
PT
 
Left  Proximal
 
Humerus
 
(PH) 
OS -2007
 
1.75
 
CMP Left
 
PH
 
A:
 
22
 
B:
 
20
 
8yrs; Disease free interval; 
continues to be disease free
3. Pt3: SS 19/
M
Left Distal Femur 
 
(DF) 
   
OS-
 
2006
 
CMP Left
 
DF 
 
Right 
 
Proximal
 
Femur
 
(PF) OS-
 
2008
 
1.9
 
CMP Right
 
PF
 
A:
 
24
 
B:
 
21
 
0.6yrs; Disease free 
interval-REC-died of 
pulmonary and cerebral
Metases
4. Pt4: VA 11/
M
Right Distal Femur
 
(DF) OS-
 
2011
 
CMP Right
 
DF
 
Right 
 
Tibia 
Diaphysis
 
OS-
2012
1.75
 
CMP Right
 
Tibia
 
A:
 
23
 
B:
 
18
 
3.5yrs; Disease free; alive
5. Pt5:MP 17/
M
Left Distal Tibia
(DT) OS -2013
CMP Left DT Left Proximal
Tibia (PT) OS-
2015
2.1 Total Tibia A: 23
B: 18
0.5yrs; Disease free 
interval; alive; infection
6. Pt 6: N 50/
M
Left Proximal Tibia
(PT) OS -2011
CMP Left PT Right Proximal
Humerus (PH)
OS– 2015
3.75 CMP Right 
PH 
A: 21
B: 19
0.5yrs; Disease free 
interval; continues to be 
disease free
 The etiology and pathogenesis of 
metachronous osteosarcoma are unknown. 
Batson et al (15) postulated that the metastases 
migrated through the vertebral venous system 
and by passed the portal, caval, and pulmonary 
circulations. It is now known that metachronous 
osteosarcoma may occur as a single lesion (16, 
17) or as multiple lesions (7, 16, 17). Fitzgerald 
et al (10) described 12 patients with multiple 
metachronous osteosarcoma with 4 patients 
developing a third metachronous tumour and 2 
patients developing a fourth metachronous 
tumour.  It was not possible to determine 
whether the metachronous sarcomas represented 
late metastases or new 'primary' tumours. We 
report 6 cases of single metachronous 
osteosarcoma in our study. There are two 
classiﬁcations for metachronous osteosarcoma 
(12, 18).
 
 The clinical and radiographic features 
generally resemble those of primary 'classic' 
osteosarcoma (1, 2).  Howat et al reported a case 
of the multifocal metachronous periosteal 
variety (7). Because the blood supply to the 
periosteum is poor compared with the blood 
supply to intramedullary bone, they considered 
their cases of periosteal osteosarcoma of primary 
origin. We found all our metachronous lesions 
having same clinical,  radiological and 
histopathological resemblance to the index 
primary tumour.
 Speculation has been raised that other pre- 
e x i s t i n g  c o n d i t i o n s ,  s u c h  a s 
Rothmund–Thomson syndrome, Paget disease, 
Fanconi anaemia, thyroid adenoma, childhood 
retinoblastoma, carcinoma of bladder and other 
genitourinary tumours, may contribute to the 
development of metachronous osteosarcoma. 
These diseases and cancerous conditions are 
known to be associated with the development of 
osteosarcoma and other malignant tumours, and 
its occurrence with osteosarcoma has been noted 
(17-21). We report all 6 cases, resembling the 
previously detected primary tumour. None of 6 
p a t i e n t s  i n  o u r  s e r i e s  h a d  b i l a t e r a l 
retinoblastoma as all patients were screened and 
were evaluated thoroughly using PET scan.
 In one of the large reported studies of 
metachronous osteosarcoma by Fitzgerald et al 
(10), the interval between discovery of the 
primary and metachronous lesions varied from 9 
months to 14 years.  Aung et al (13) reported the 
median latency interval between the diagnosis of 
the primary and the metachronous tumours was 
1.5 years.  Corradi et al (14) reported the interval 
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between diagnosis of primary osteosarcomas 
and metachronous tumour, ranging from 7 to 171 
months (median: 21 months). In our series, the 
interval between discovery of the primary 
tumours and the metachronous tumors varied 
from 20 to 41 months (mean: 27 months, i.e. 2.4 
years). 
 In the study by Fitzgerald et al (10), the 
survival post-metachronous tumour excision 
and endoprosthetic replacement varied from 5 
months to 11 years.  Aung et al (13) reported that 
survival was found to be correlated with time to 
development of the metachronous tumour and 
longer time interval from diagnosis of the 
primary to the metachronous osteosarcoma 
correlates with the prognosis. In study by Jaffe et 
al (22), the 5-year post-metachronous survival 
rate in patients who developed metachronous 
tumours 24 months from and after diagnosis of 
the primary osteosarcoma were 8% and 61%, 
respectively. In our study, the survival varied 
from 8 months to 8 years with two patients 
succumbing to metastasis at 8th and 18th month. 
However, we could not conclude that time 
interval from diagnosis correlated with 
prognosis or survival. 
Conclusion 
 With improvement in the cure rate, 
metachronous osteosarcoma should be 
recognized as important sequelae in long-term 
survivor. Serial surveillance is required to permit 
early detection and successful therapeutic 
i n t e rven t ion .  Upon  the  d i s cove ry  o f 
metachronous osteosarcoma, it should be treated 
always with curative intent. Limb salvage 
surgery  us ing  cus tom endopros the t ic 
replacement provides predictable results in the 
management of metachronous tumours with 
good to excellent functional outcome.
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